文献速递主动脉疾病颈动脉与弓上血管

胸主动脉腔内修复术中锁骨下动脉血运重建的中期结果

Midterm outcomes of subclavian artery revascularization in the setting of thoracic endovascular aortic repair.
PubMed 文献 · J Vasc Surg · 2020-02-22

该研究回顾2000至2015年1516例TEVAR患者,其中282例(19%)同期行锁骨下动脉血运重建(SAR)。SAR以颈动脉-锁骨下动脉旁路为主(93%)。30天同侧卒中率3.5%,30天全因死亡率4.6%,1、5、10年总生存率分别为82%、60%、42%。颈动脉-锁骨下动脉旁路1、2、5年一期通畅率分别为99.5%、98.9%、98.0%,锁骨下动脉转位均为100%。

要点

  • TEVAR中SAR以颈动脉-锁骨下动脉旁路为主(93%),30天同侧卒中率3.5%。
  • 颈动脉-锁骨下动脉旁路1、2、5年一期通畅率分别为99.5%、98.9%、98.0%。
  • SAR总体30天全因死亡率4.6%,1、5、10年总生存率分别为82%、60%、42%。

核心结论

  • 在TEVAR背景下行SAR与低发病率、持久长期通畅率和较低的再干预需求相关。

研究设计与样本

  • 回顾性数据库查询研究,纳入2000至2015年接受TEVAR的1516例患者,其中282例(19%)同时行SAR。
  • SAR术式包括颈动脉-锁骨下动脉旁路269例(93%)和锁骨下动脉转位19例(7%)。
  • SAR时机:76%在TEVAR前、14%与TEVAR同时、10%在TEVAR后。

主要发现

  • TEVAR最常见适应证为主动脉瘤(56%)、慢性主动脉夹层伴动脉瘤样变(23%)和主动脉夹层(13%)。
  • 30天同侧卒中率为3.5%;8例(2.8%)非计划重返手术室(2.1%血肿清除,0.7%乳糜漏处理);6例(2.1%)神经损伤。
  • 平均随访4.2年,30天全因死亡率为4.6%;1、5、10年总生存率分别为82%、60%、42%,中位生存7.2年。
  • 随访中4例出现一期通畅失败,均为颈动脉-锁骨下动脉旁路;颈动脉-锁骨下动脉旁路1、2、5年一期通畅率分别为99.5%、98.9%、98.0%,锁骨下动脉转位均为100%。

临床怎么用

  • 在TEVAR需要覆盖锁骨下动脉时,可考虑行SAR(尤其颈动脉-锁骨下动脉旁路),其围手术期并发症和远期通畅率可接受。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The outcomes of subclavian artery revascularization (SAR) have been examined extensively in the setting of atherosclerotic occlusive disease but have been poorly characterized in the setting of thoracic endovascular aortic repair (TEVAR). As trials for branched thoracic endovascular stent grafts materialize, the outcomes of the subclavian artery branched prosthesis will need to be compared with TEVAR with SAR by carotid-subclavian bypass or subclavian transposition. METHODS: A database of 1516 patients undergoing TEVAR from 2000 to 2015 was queried. Of those undergoing TEVAR, 19% (282 patients) also underwent SAR. Patient demographics, TEVAR indication, 30-day morbidity and mortality, and midterm patency and survival were analyzed. RESULTS: During the study period, 282 patients underwent 288 SARs in the setting of TEVAR. A total of 269 (93%) carotid-subclavian bypasses and 19 (7%) subclavian artery transpositions were performed; 76% of the SARs occurred before TEVAR, 14% occurred concurrently with TEVAR, and 10% occurred after TEVAR. The most common indications for TEVAR was aortic aneurysm (56%), chronic aortic dissection with aneurysmal degeneration (23%), and aortic dissections (13%). The 30-day ipsilateral stroke rate was 3.5%. Eight patients (2.8%) underwent an unplanned return to the operating room (2.1% for hematoma evacuation and 0.7% for management of chyle leak). Six patients (2.1%) sustained a nerve injury. The mean follow-up was 4.2 years. All-cause 30-day mortality was 4.6%. The overall survival rates at 1 year, 5 years, and 10 years were 82%, 60%, and 42%, respectively. The median survival was 7.2 years. Four patients were found to have a failure in primary patency during follow-up. All four patients had undergone a carotid-subclavian bypass. The 1-, 2-, and 5-year primary patency rates were 99.5%, 98.9%, and 98.0%, respectively, for carotid-subclavian bypass and 100% for carotid-subclavian transposition. CONCLUSIONS: During our 16-year study, we found SAR in the setting of TEVAR to be associated with low morbidity, durable long-term patency, and infrequent need for reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Protack CD, Smith A, Moennich LA, et al. Midterm outcomes of subclavian artery revascularization in the setting of thoracic endovascular aortic repair. J Vasc Surg. 2020. PMID: 32093914. doi:10.1016/j.jvs.2019.11.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。